FIG. 2.

Intranasal boosting with rAd85A results in increased ex vivo (A) and cultured ELISPOT (B) responses. (A) PBMC were prepared before the rAd85A boost (week 7, black bar) and at week 9 (gray bar) of the experiment and stimulated with a pool of immunodominant Ag85A-derived peptides. Results are expressed as mean SFC/10⁶ PBMC ± SEM (n = 3). (B) SFC were determined after culture with rAg85A for the cultured ELISPOT protocol at week 7 (black bar) and week 10 (gray bar) of the experiment. ELISPOT assays were performed 13 days after culture initiation, using the synthetic peptide cocktail used for panel A in the absence of additional antigen-presenting cells. Results are expressed as mean SFC/10⁶ cells ± SEM (n = 3). *, P < 0.05 (unpaired t test).